1.64
-0.03(-1.80%)
Currency In USD
| Previous Close | 1.67 |
| Open | 1.72 |
| Day High | 1.74 |
| Day Low | 1.62 |
| 52-Week High | 3.78 |
| 52-Week Low | 0.86 |
| Volume | 4.95M |
| Average Volume | 2.86M |
| Market Cap | 368.56M |
| PE | -1.67 |
| EPS | -0.98 |
| Moving Average 50 Days | 1.36 |
| Moving Average 200 Days | 1.29 |
| Change | -0.03 |
If you invested $1000 in Allogene Therapeutics, Inc. (ALLO) since IPO date, it would be worth $65.6 as of January 14, 2026 at a share price of $1.64. Whereas If you bought $1000 worth of Allogene Therapeutics, Inc. (ALLO) shares 5 years ago, it would be worth $52.78 as of January 14, 2026 at a share price of $1.64.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T
GlobeNewswire Inc.
Jan 08, 2026 1:30 PM GMT
1H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune Disease Interim Futility Analysis of MRD Clearance from the Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
GlobeNewswire Inc.
Dec 15, 2025 10:39 PM GMT
Arbitration Ruling Reaffirms Allogene’s Full Control of Cemacabtagene Ansegedleucel (Cema-Cel)Decision Reconfirms Allogene’s Expanded Sub-License Covering EU and UK Rights with Options for Japan and China, Clearing the Path for Allogene to Acquire Fu
Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update
GlobeNewswire Inc.
Nov 06, 2025 9:05 PM GMT
Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) ALPHA3 Positions Company at the Forefront of MRD-guided, Earlier-Line Oncology TreatmentAdditional Sites in Aust